$438.28
-8.98(-2.01%)
Mkt Cap $111.3B
$366.54
$509.50
52-Week Range
At a Glance
AI-generatedVertex Pharmaceuticals reported strong financial performance for fiscal year 2025, ending December 31, 2025.
Revenue breakdown: TRIKAFTAKAFTRIO (89.2%), Manufactured Product Other (7.6%), ALYFTREK (2.5%).
8-K
Vertex Pharmaceuticals has completed submission of its rolling BLA for povetacicept seeking accelerated approval for IgAN treatment in adults, using a priority review voucher for expedited six-month FDA review.$111.3B
Market Cap
$12.0B
Revenue
$4.0B
Net Income
Employees6,100
Fundamentals
How The Business Makes Money
Revenue by Segment
TRIKAFTAKAFTRIO89.2%($29.5B)
Manufactured Product Other7.6%($2.5B)
ALYFTREK2.5%($838M)
CASGEVY0.4%($126M)
JOURNAVX0.2%($60M)
Collaborativeand Royalty0.1%($31M)
Revenue by Geography
US44.6%($20.3B)
Outsidethe United States27.7%($12.6B)
Europe22%($10.0B)
Other Countries Outsideofthe United Statesand Europe5.7%($2.6B)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000875320
ISINUS92532F1003
CUSIP92532F100
Phone617 341 6100
Address50 Northern Avenue, Boston, MA, 02210, US
SEC EDGAR